PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
| Autor: | Peter L. Choyke, Harriet C. Thoeny, Masoom A. Haider, Katarzyna J. Macura, Jeffrey C. Weinreb, Mitchell D. Schnall, Faina Shtern, Sadna Verma, François Cornud, Clare M. Tempany, Daniel Margolis, Jelle O. Barentsz |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Standardization Urology Prostatic Hyperplasia Risk Assessment Article 030218 nuclear medicine & medical imaging Terminology 03 medical and health sciences Prostate cancer 0302 clinical medicine Prostate Terminology as Topic Image Interpretation Computer-Assisted medicine Humans Medical physics Endoscopic Ultrasound-Guided Fine Needle Aspiration Multiparametric Magnetic Resonance Imaging Neoplasm Staging Gynecology medicine.diagnostic_test business.industry Prostatic Neoplasms Magnetic resonance imaging medicine.disease Magnetic Resonance Imaging PI-RADS Radiology Information Systems medicine.anatomical_structure Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] 030220 oncology & carcinogenesis Risk assessment business |
| Zdroj: | European Urology, 69, 16-40 European Urology, 69, 1, pp. 16-40 |
| ISSN: | 0302-2838 |
| DOI: | 10.1016/j.eururo.2015.08.052 |
| Popis: | Item does not contain fulltext The Prostate Imaging - Reporting and Data System Version 2 (PI-RADS v2) is the product of an international collaboration of the American College of Radiology (ACR), European Society of Uroradiology (ESUR), and AdMetech Foundation. It is designed to promote global standardization and diminish variation in the acquisition, interpretation, and reporting of prostate multiparametric magnetic resonance imaging (mpMRI) examination, and it is based on the best available evidence and expert consensus opinion. It establishes minimum acceptable technical parameters for prostate mpMRI, simplifies and standardizes terminology and content of reports, and provides assessment categories that summarize levels of suspicion or risk of clinically significant prostate cancer that can be used to assist selection of patients for biopsies and management. It is intended to be used in routine clinical practice and also to facilitate data collection and outcome monitoring for research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect